


# Quantitative Perfusion Analysis for Transcatheter Intraarterial Perfusion MR Imaging

D. Wang<sup>1</sup>, J. Chung<sup>2</sup>, R. Lewandowski<sup>2</sup>, R. Tang<sup>2</sup>, R. Klein<sup>2</sup>, R. Omary<sup>1,3</sup>, and A. Larson<sup>1,3</sup>

<sup>1</sup>Departments of Radiology and Biomedical Engineering, Northwestern University, Chicago, IL, United States, <sup>2</sup>Department of Radiology, Northwestern University, Chicago, IL, United States, <sup>3</sup>Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States

**Introduction:** Transcatheter arterial embolization (TAE) and chemoembolization (TACE) are established treatment methods for unresectable liver tumor. **TR**anscatheter **I**ntraarterial **P**erfusion (**TRIP**)-MRI is an intra-procedural technique to monitor liver tumor perfusion changes during TAE [1] and TACE [2]. However, previous developed TRIP-MRI approaches either used semi-quantitative perfusion analyses which have poorly-defined links to blood flow, or used a peak gradient method [3] which can oversimplify the description of contrast tracer kinetics, to calculate blood flow. In this study, we presented a potentially superior quantitative TRIP-MRI perfusion analysis approach, and evaluated its efficacy in a gel perfusion phantom and in rabbits with VX2 liver tumors during TAE.

**Methods:** All experiments were performed using a 1.5T clinical MRI scanner (Siemens Magnetom Espree). In phantom studies, we used a chromatography column packed with Sephadex gel as a perfusion phantom. The phantom flow rate was adjusted from 24 mL/min to 2 mL/min at a 2 mL/min interval, and TRIP-MRI measurement was performed at each flow rate. In animal studies, we surgically implanted VX2 carcinoma into the left liver lobe of 12 rabbits. 3 weeks after implantation, we catheterized each rabbit under angiographic guidance to super-selectively deliver 40-120 μm embolic microspheres to liver tumors. After rabbits were transfer to MRI scanner, TRIP-MRI measurements were performed before and after TAE. A quantitative TRIP-MRI measurement involved 3D B<sub>1</sub> mapping using catalyzed double-angle method (60°/120°) [4], baseline 3D R<sub>10</sub> mapping using GRE variable flip angle method (2°, 9°, 15°, 19°), and dynamic 3D R<sub>1</sub> mapping using dynamic GRE sequence at 15° flip angle after intraarterial injection of Gd-DTPA contrast agent. Other dynamic imaging parameters included: phantom studies: TR/TE = 5/1.62 ms, 320×160×40 mm<sup>3</sup> FOV, 1.2 sec sampling rate; animal studies: TR/TE = 6/1.62 ms, 200×113×40 mm<sup>3</sup> FOV, 1.6 sec sampling rate. With B<sub>1</sub> calibration and baseline R<sub>10</sub> map, an R<sub>1</sub> map time series and further contrast



**Fig 1.** Representative TRIP-MRI phantom concentration time curves and model curve fittings at different flow rates.

bolus injection temporarily suppress antegrade blood flow and control the maximum vascular contrast agent concentration at the catheter tip immediately proximal to the tumor tissues, we estimated C<sub>p</sub>(t) using prior information about the bolus injection parameters (Eq. 2).

$$C_i(t) = v_p C_p(t) + K^{trans} \int_0^t C_p(\tau) \exp(-k_{ep}(t-\tau)) d\tau \quad (1)$$


modified Kety model to describe contrast tracer pharmacokinetics [5] (Eq. 1). Given that the super-selective transcatheter

$$C_p(t) = C_{inject} \int_0^t C_c(\tau) \exp(-\beta(t-\tau)) d\tau / \max\left(\int_0^t C_c(\tau) \exp(-\beta(t-\tau)) d\tau\right) \quad (2)$$


where  $C_c(t) = \begin{cases} 0 & t < T_{start} \text{ or } t > T_{end} \\ 1 & T_{start} \leq t \leq T_{end} \end{cases}$  is a normalized boxcar function, with 0 meaning no contrast solution being

injected, 1 meaning contrast solution being injected, and T<sub>start</sub> and T<sub>end</sub> representing the beginning and ending times for the transcatheter injection of the contrast solution. Perfusion maps were generated by fitting combined Eqs. 1 and 2. As K<sup>trans</sup> is primarily representative of blood flow under flow-limited conditions expected in extra-cranial tumor microvasculature, we therefore chose K<sup>trans</sup> as the kinetic parameter to reflect liver tumor perfusion alterations during TAE. Whole tumor regions-of-interest were drawn on K<sup>trans</sup> maps to measure intra-procedural tumor K<sup>trans</sup> values. K<sup>trans</sup> values before and after TAE were compared using paired t-tests with α=0.05.


**Results:** The phantom C<sub>i</sub>(t) curves, estimated C<sub>p</sub>(t) curves, and associated model curve fittings for different flow rates are shown in Fig. 1. The measured K<sup>trans</sup> demonstrated a strong linear correlation to flow rate during our perfusion phantom studies (R<sup>2</sup> = 0.9876, P < .0001, Fig. 2). In animal studies, TAE and quantitative TRIP-MRI were successfully performed in 12 rabbits with 19 liver tumors. Fig. 3 shows representative voxel-wise tumor C<sub>i</sub>(t) curves, estimated C<sub>p</sub>(t) curves, and associated model curve fittings from two representative rabbits. Fig. 4 shows T2-weighted image, TRIP-MRI peak enhanced image, and corresponding K<sup>trans</sup> maps before and after TAE from one representative rabbit. The tumor K<sup>trans</sup>



**Fig 2.** Regression plot demonstrates a strong linear relationship between measured K<sup>trans</sup> and flow rate in the perfusion phantom.



**Fig 3.** Representative TRIP-MRI voxel-wise tumor concentration time curves and the model curve fittings before and after TAE.



**Fig 4.** Images from one representative rabbit. T2-weighted image, TRIP-MRI peak enhanced image depict tumor positions (arrows). Corresponding K<sup>trans</sup> maps demonstrate clear perfusion reductions after TAE.

decreased significantly from 0.468 (95% CI: 0.328-0.607) pre-TAE to 0.093 (95% CI: 0.061-0.126) post-TAE (1/min, P < .0001), with a mean percentage reduction of 77.8% (95% CI: 70.3%-85.3%).

**Conclusions:** Our study successfully evaluated the efficacy of the proposed perfusion analysis method for TRIP-MRI datasets in a perfusion phantom, and demonstrated the use of quantitative TRIP-MRI to monitor reductions in liver tumor perfusion during TAE. Quantitative TRIP-MRI measurements offer the potential to target optimal embolic endpoint for TAE and TACE, which maximizes tumor response and minimizes toxicity to normal liver tissues.

**References:** [1] Wang et al., Radiology 2007;245:130-139 [2] Larson et al., Radiology 2008;246:964-971 [3] Wang et al., Mag Reson Med 2008;60:970-975 [4] Wang et al., NMR Biomed 2009;22:882-890 [5] Roberts et al., JMIR 2006;23:554-563.

**Acknowledgements:** The authors wish to acknowledge grant support from NIH R01 CA126809-01A2 and R01 CA134719-01; the SIR Foundation; and the Rosenberg Family Cancer Research Fund.